2 research outputs found
Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in
western countries. CLL evolution is frequently indolent, and treatment is mostly reserved
for those patients with signs or symptoms of disease progression. In this work, we used
RNA sequencing data from the International Cancer Genome Consortium CLL cohort
to determine new gene expression patterns that correlate with clinical evolution.We
determined that a 290-gene expression signature, in addition to immunoglobulin heavy
chain variable region (IGHV) mutation status, stratifies patients into four groups with
notably different time to first treatment. This finding was confirmed in an independent
cohort. Similarly, we present a machine learning algorithm that predicts the need for
treatment within the first 5 years following diagnosis using expression data from 2,198
genes. This predictor achieved 90% precision and 89% accuracy when classifying
independent CLL cases. Our findings indicate that CLL progression risk largely correlates
with particular transcriptomic patterns and paves the way for the identification of high-risk
patients who might benefit from prompt therapy following diagnosis.S
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study
We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P 15% of cells were positive in anaplastic lymphoma kinase-positive and -negative anaplastic large-cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re-evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological sub-classification, and response level to first-line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.This study was sponsored by Takeda